COMPETITION WATCHDOG FINES NOVARTIS AND ROCHE TRY 278M

The Competition Board imposed fines on pharmaceutical manufacturers Novartis and Roche for trying to push a more expensive medicine used for eye diseases over a cheaper one. The decision was taken unanimously, according to the statement from the Competition Board. As a result of the investigation carried out within the scope of Article 4 of the Competition Law, Novartis and Roche were issued administrative fines of TRY 165.4m and TRY 112.9m, respectively. The companies have the right to appeal the decision in the Ankara Administrative Courts within 60 days.